Cancer Immunology, Immunotherapy

Prostate cancer vaccines: the long road to clinical application

• Review

Constantin N. Baxevanis, Michael Papamichail, Sonia A. Perez

DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma

• Original Article

Ming-Ru Wu, Tong Zhang, Andre Alcon, Charles L. Sentman

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

• Original Article

Elias J. Sayour, Pat McLendon, Roger McLendon, Gabriel De Leon, Renee Reynolds, Jesse Kresak, John H. Sampson, Duane A. Mitchell

Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice

• Original Article

Hiroyasu Ito, Tatsuya Ando, Hideyuki Ogiso, Yuko Arioka, Mitsuru Seishima

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)

• Original Article

Mario E. Lacouture, John C. Morris, Donald P. Lawrence, Antoinette R. Tan, Thomas E. Olencki, Geoffrey I. Shapiro, Bruce J. Dezube, Jay A. Berzofsky, Frank J. Hsu, Joan Guitart

Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide

• Original Article

Mélanie Morin-Brureau, Kirsten M. Hooper, Michael Prosniak, Sami Sauma, Larry A. Harshyne, David W. Andrews, D. Craig Hooper

The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma

• Original Article

Tasha Hughes, Matthew Klairmont, Joseph Broucek, Gail Iodice, Sanjib Basu, Howard L. Kaufman

Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence

• Original Article

Marcin Okroj, Emelie Holmquist, Elise Nilsson, Lola Anagnostaki, Karin Jirström, Anna M. Blom

Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination

• Original Article

Dionisia Quiroga, Yasser A. Aldhamen, Daniel M. Appledorn, Sarah Godbehere, Andrea Amalfitano

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression

• Original Article

Masanori Noguchi, Gaku Arai, Kazumasa Matsumoto, Seiji Naito, Fukuko Moriya, Shigetaka Suekane, Nobukazu Komatsu, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh

Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

• Original Article

Oliver Klein, Ian D. Davis, Grant A. McArthur, Li Chen, Andrew Haydon, Phillip Parente, Nektaria Dimopoulos, Heather Jackson, Kun Xiao, Eugene Maraskovsky, Wendie Hopkins, Rodica Stan, Weisan Chen, Jonathan Cebon

“Tumor immunology meets oncology” (TIMO) X, May 23–24, 2014, Halle/Saale, Germany

• Meeting Report

Dagmar Quandt, Barbara Seliger

Acknowledgement

• ACKNOWLEDGEMENT TO REVIEWERS